Compare Harley-Davidson Inc (HOG) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Harley-Davidson Inc vs Zimmer Biomet Holdings Inc — how do they compare? Harley-Davidson Inc trades at $25.99 (market cap $2.78B), while Zimmer Biomet Holdings Inc trades at $96.54 (market cap $18.55B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 6.7× Harley-Davidson Inc's market cap, and Harley-Davidson Inc pays the higher dividend (2.75%). Which is the better fit depends on your goals.
| HOG | ZBH | |
|---|---|---|
Market Cap | $2.78B | $18.55B |
Sector | Consumer Cyclical | Health |
52-Week High | $31.03 | $107.71 |
52-Week Low | $17.19 | $79.58 |
Enterprise Value | $3.19B | $25.61B |
Dividend Yield | 2.75% | 0.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Harley-Davidson (HOG) trades at $25.95, down 0.57% with a bullish technical signal. The company reported Q2 2026 EPS of $0.75 beating estimates of $0.645, though revenue declined to $4.47B in 2025 from $5.8B in 2022. Valuation metrics appear reasonable with P/E of 14.84 and P/S of 0.72. Recent news highlights production returning to US facilities and raised 2026 guidance following stronger North American sales.
The outlook remains cautiously optimistic with analyst consensus at $26.00 target. Key opportunities include cost-cutting initiatives and domestic production advantages, while risks involve ongoing revenue pressure, competitive threats from Indian Motorcycle, and margin compression from rising raw material costs evident in recent quarterly results.
ZBH trades at $96.04, down 1.78% today, with a bullish technical signal from moving averages and a consensus analyst price target of $103.56. Recent Q2 2026 earnings beat expectations with EPS of $2.07 versus $2.01 expected, and the company raised its 2026 outlook. Revenue growth remains steady, with 2025 revenue at $8.23 billion and a net income margin of 8.56%.
The outlook is positive given earnings momentum and raised guidance, but risks include competitive pressures and debt levels, with the debt-to-asset ratio rising to 32.57% in 2025. Analyst sentiment is mixed with 40% buy ratings, offering a potential 7.8% upside to the consensus target, though investors should monitor margin trends and debt management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Harley-Davidson Inc
Harley-Davidson is a global leading manufacturer of heavyweight motorcycles, merchandise, parts, and accessories. It sells custom, cruiser, and touring motorcycles and offers a complete line of Harley-Davidson motorcycle parts, accessories, riding gear, and apparel, as well as merchandise. Harley-Davidson Financial Services provides wholesale financing to dealers and retail financing and insurance brokerage services to customers. Harley has historically captured about half of all heavyweight domestic retail motorcycle registrations, a metric it had ceded in 2020 as it repositioned the business, but a level it is working back toward. In recent years the firm has expanded into the adventure touring market with its Pan America model and into electric with the LiveWire brand.
Read more on HOG →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
